MIPM Mammendorfer Institut fuer Physik und Medizin GmbH researches, develops, plans and sells medical systems with a focus on MRI-compatible patient monitoring. The company manufactures all products at its main site in Mammendorf and describes its products as niche items with high production complexity and specific know-how. MIPM distributes its products in more than 110 countries via a dealer network and primarily serves customers in radiology and anaesthesia. On average during the year the company employed 66 staff (previous year: 68) and 11 trainees; management proposes to carry forward the net profit of EUR 1,536,267.08. MIPM Mammendorfer Institut für Physik und Medizin GmbH is a family business.
Forschung, Entwicklung, Planung und der Vertrieb medizinischer Systeme und alle damit in Zusammenhang stehenden Geschäfte.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 68868 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Andreas Klement | Geschäftsführer(in) | Merching |
| Jennifer Rosenheimer | Geschäftsführer(in) | Oberschweinbach |
| Michael Rosenheimer | Geschäftsführer(in) | Günzlhofen |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 68868 (as of 1 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 06.05.2022 | Business Address Change | Oskar-von-Miller Str. 6-7, 82291 Mammendorf |
| 09.09.2021 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 17.12.2010 | Business Address Registered | Oskar-von-Miller-Str. 6, 82291 Mammendorf |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 09.09.2021 | Share Capital Set | — | 100.000 € |
| 04.12.2001 | Share Capital Set | — | 100.000 DM |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 68868 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€7.2M2 | €494,944 | €10,551,326 | — |
| 2024 | Rohergebnis€9.1M2 | €1,546,345 | €10,097,493 | — |
| 2023 | Rohergebnis€8.5M2 | €1,566,760 | €9,313,510 | — |
| 2022 | Rohergebnis€8.2M2 | €1,185,717 | €7,955,336 | — |
| 2021 | Rohergebnis€6.7M2 | €1,019,667 | €6,561,130 | — |
| 2020 | small company1 | €1,251,021 | €5,287,744 | — |
| 2019 | small company1 | €867,311 | €5,941,112 | — |
| 2018 | ≤ €12M1 | €1,698,739 | €6,115,656 | — |
| 2017 | small company1 | €1,279,010 | €3,637,462 | — |
| 2016 | small company1 | €865,209 | €3,722,952 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 68868 (as of 1 November 2026)
Rayonex Biomedical GmbH
Lennestadt · Forschung und Entwicklung im Bereich Biotechnologie
F&E GmbH
Kiel · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
Silony Medical GmbH
Leinfelden-Echterdingen · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,320,440 | 90.8% |
| Depreciation | €435,296 | 9.2% |
| Interest & Similar | €1,384 | 0.0% |
